Breaking News

At the frontier of brain tumour research, leave no stone unturned

With the Government set to invest an additional £20 million into the research, diagnosis and development of treatments ...

Cell and Gene Therapy Catapult announces major UK investment in skills and capabilities

£3 million in Government investment to drive forward the Life Sciences Industrial Strategy via apprenticeships and ...

New risk assessment on safe levels of opium alkaloids in poppy seeds

The European Food Safety Authority (EFSA) updated its risk assessment of opium alkaloids in poppy seeds, confirming ...

Patient centricity: a winning formula

Industry has taken a collective pause in an effort to re-evaluate and rethink longstanding approaches to drug ...

Winners of the Cleanroom Technology 2018 Awards announced

Industry awards have been presented at this year's international conference in Birmingham

Ixico signs contract with top 10 pharma company

The deal will provide specialist imaging clinical trial services for trial participants with Huntington’s disease

Accelerating drug discovery

Angharad Baldwin of Manufacturing Chemist speaks to Dr Trevor Perrior, CSO of Domainex, about the development of a new ...

New project to enhance nanomedicine development

The Centre for Process Innovation, has launched a new collaborative project to strengthen its nanoformulation ...

Synpromics receives £1.9m grant from Scottish Enterprise

The funds will expand Synpromics’ R&D programmes in gene regulation for cell and gene medicines

Meet… Harald Castler

As President of Getinge Life Science and former Chairman of Halmstad University, Harald sees his role as facilitating ...

Advances in medical technology

Overhauling operating models to create digital value

Continuous teaching and research at DiPP

Dr Kevin Robinson was on site when the University of Sheffield officially opened its fully integrated continuous ...

Cancer Research UK launches Brain Tumour Awards

The aim of the awards is to help advance understanding about the biology of the disease and the challenges translating ...

Biogen and Neurimmune announce option exercise for Aducanumab

The transaction will increase the profit potential of aducanumab for Biogen and provides near-term capital to Neurimmune